Brief: Allovir Announces To Complete Enrollment In Three Phase 3 Posoleucel Studies

Kalaris Therapeutics

09/01/2023 12:43

Jan 9 (Reuters) - Allovir Inc  ALVR.O :
    * ALLOVIR ANNOUNCES PLANS TO COMPLETE ENROLLMENT IN THREE
PHASE 3
POSOLEUCEL STUDIES IN 2023
    * ALLOVIR INC - COMPLETION OF ENROLLMENT OF ALL THREE
POSOLEUCEL
PHASE 3 REGISTRATIONAL TRIALS ANTICIPATED BY END OF 2023 AND
DATA READOUTS IN 2024
    * ALLOVIR INC - TOPLINE RESULTS OF POSOLEUCEL PHASE 2 BKV
TREATMENT STUDY IN KIDNEY TRANSPLANT PATIENTS EXPECTED IN 1Q
2023
    * ALLOVIR INC - EXPECTS TO INITIATE CLINICAL DEVELOPMENT OF
ALVR107 UPON COMPLETION OF POSOLEUCEL PHASE 3 REGISTRATIONAL
STUDIES
    * ALLOVIR INC - AS OF DECEMBER 31, 2022, COMPANY'S CASH
BALANCE
WAS $234 MILLION
    * ALLOVIR INC - FOR FISCAL YEAR 2023 EXPECTS OPERATING
EXPENSES TO
BE IN RANGE OF $150 MILLION TO $170 MILLION, EXCLUDING NON-CASH
STOCK COMPENSATION EXPENSES

Source text for Eikon:  ID:nBw68WjyLa 
Further company coverage:  ALVR.O 
 ((Reuters.Briefs@thomsonreuters.com;))